Short Interest in Genfit S.A. (NASDAQ:GNFT) Rises By 59.0%

Genfit S.A. (NASDAQ:GNFT - Get Free Report) was the target of a significant growth in short interest in January. As of January 31st, there was short interest totalling 101,300 shares, a growth of 59.0% from the January 15th total of 63,700 shares. Based on an average daily volume of 8,200 shares, the short-interest ratio is currently 12.4 days. Currently, 0.2% of the shares of the stock are short sold.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a "buy" rating and issued a $13.00 price objective on shares of Genfit in a report on Friday, February 7th.

Institutional Investors Weigh In On Genfit

An institutional investor recently bought a new position in Genfit stock. Millennium Management LLC acquired a new stake in shares of Genfit S.A. (NASDAQ:GNFT - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 166,375 shares of the company's stock, valued at approximately $611,000. Millennium Management LLC owned approximately 0.33% of Genfit at the end of the most recent quarter. 2.24% of the stock is currently owned by institutional investors and hedge funds.

Genfit Stock Down 0.5 %

Shares of GNFT traded down $0.02 during trading hours on Wednesday, hitting $3.84. 16,757 shares of the stock were exchanged, compared to its average volume of 8,449. The stock's 50-day moving average price is $3.75 and its two-hundred day moving average price is $4.42. Genfit has a 12-month low of $3.35 and a 12-month high of $6.42. The company has a quick ratio of 3.74, a current ratio of 3.74 and a debt-to-equity ratio of 0.61.

About Genfit

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.